Goldman Sachs Group set a €114.00 ($132.56) price target on MorphoSys (ETR:MOR) in a report issued on Thursday, Borsen Zeitung reports. The firm currently has a neutral rating on the stock.
A number of other research analysts have also issued reports on MOR. Deutsche Bank set a €125.00 ($145.35) price target on MorphoSys and gave the stock a buy rating in a research report on Thursday. Independent Research set a €96.00 ($111.63) price target on MorphoSys and gave the stock a neutral rating in a research report on Thursday. JPMorgan Chase & Co. set a €120.00 ($139.53) price target on MorphoSys and gave the stock a buy rating in a research report on Thursday, April 4th. Berenberg Bank set a €108.00 ($125.58) price target on MorphoSys and gave the stock a neutral rating in a research report on Friday, February 15th. Finally, Royal Bank of Canada set a €65.00 ($75.58) price target on MorphoSys and gave the stock a sell rating in a research report on Thursday, March 14th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the stock. The stock has a consensus rating of Hold and a consensus price target of €100.78 ($117.18).
Shares of MOR stock opened at €91.50 ($106.40) on Thursday. The company has a quick ratio of 7.53, a current ratio of 7.75 and a debt-to-equity ratio of 8.65. MorphoSys has a 1 year low of €76.45 ($88.90) and a 1 year high of €124.90 ($145.23). The firm has a market cap of $2.89 billion and a price-to-earnings ratio of -49.22.
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Featured Article: Options Trading – What is a Straddle?
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.